Soleno reports death of patient who took genetic disorder treatment
Sept 10 (Reuters) - Soleno Therapeutics SLNO.O reported on Wednesday the death of a 17 year old male who was on the company's treatment for patients who experience feelings of intense and persistent hunger.
The company said the treating physician has reported that the death is not related to the treatment.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







